Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.
about
Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week TrialHIV drug therapy duration; a Swedish real world nationwide cohort study on InfCareHIV 2009-2014.Effectiveness and safety of rilpivirine, a non-nucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV-1: a meta-analysis.Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients.Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz.Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art.Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen.Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz.Neurological Complications of HIV Infection.A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population.Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 t
P2860
Q35652019-39706A9E-8BA2-4AE7-BE39-3F217656C9B8Q36282702-14416B73-51B4-45C9-96A6-65C7D61F3C46Q38272654-0B76DA25-EFED-43BC-8604-39C001EDE8DCQ38802093-5416C2E6-6750-4B6F-8BC1-4BF6669FF299Q38976612-9F1F3C41-FF83-4012-B855-40CE1354542BQ39004638-DCC4C679-F75E-47B2-A5C1-4FB614534A26Q40132756-60D5F720-2CBC-4EF8-BD9E-EEAE8DA3DF30Q40513800-E69442C7-D481-439C-9EE6-BA5B3B2A93A9Q42592784-3D906E8E-608A-48BD-AFB9-8FF84ABA198FQ52774286-3B77E438-9CA0-488C-8E5C-89EDB20EEAA5Q54211761-542E9BDD-6978-4821-B74E-265DFB020772Q58254289-C98B8E33-EE25-4FA3-989D-0AE799CA341E
P2860
Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Neurological and psychiatric t ...... infected patients at 48 weeks.
@ast
Neurological and psychiatric t ...... infected patients at 48 weeks.
@en
Neurological and psychiatric t ...... infected patients at 48 weeks.
@nl
type
label
Neurological and psychiatric t ...... infected patients at 48 weeks.
@ast
Neurological and psychiatric t ...... infected patients at 48 weeks.
@en
Neurological and psychiatric t ...... infected patients at 48 weeks.
@nl
prefLabel
Neurological and psychiatric t ...... infected patients at 48 weeks.
@ast
Neurological and psychiatric t ...... infected patients at 48 weeks.
@en
Neurological and psychiatric t ...... infected patients at 48 weeks.
@nl
P2093
P2860
P356
P1433
P1476
Neurological and psychiatric t ...... infected patients at 48 weeks.
@en
P2093
A Antinori
ECHO and THRIVE study groups
J V Madruga
P2860
P304
P356
10.1111/HIV.12012
P577
2013-01-09T00:00:00Z